The Blue Cross Blue Shield Federal Employee Program criteria for Saxenda and Wegovy, policy 5.99.030, effective July 1, 2026, require prior participation in a comprehensive weight management program, and at renewal that an adult has lost at least 5 percent of baseline body weight OR the patient has continued to maintain their initial 5 percent weight loss. That is one of the few places in these documents where maintaining rather than losing is written down as a reason to keep paying
Heres what most people follow: Weeks 14: Adaptation phase
Blood was obtained via cardiac puncture and centrifuged at 4000 rpm at 4 C for 10 min to collect plasma
In fact, they hinted that if results are ready in time, they might submit retatrutide to the FDA in late 2025 , which could potentially lead to approval in 2026
"I can go and have dinner with friends and not have to eat every piece of bread on the table." Vanessa Williams For musician and model Vanessa Williams, menopause wasn't kind to her body